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The volume of the HR-CTV not covered with the prescribed 
isodose was 19.8 ccm. Oblique needles applied at the time of 
the second application contributed significantly to a better 
dose coverage of HR-CTV (D90=109%, D100=55%, V100=93%). 
The part of the volume not sufficiently covered with the 
prescribed dose in the first application was boosted using 
only oblique needles at the end of the second treatment until 
the dose restrictions for the OAR were reached (Figure 1b). 
DVH parameters for HR-CTV of the second application were 
improved accordingly: D90=119%, D100=61%, V100=96%. The 
volume of the HR-CTV not covered with the prescribed 
isodose was reduced to 2.4 ccm. The position on the ring, 
oblique angle and the insertion depth of the oblique needles 
in the second application were measured on the MR images 
and compared with the pre-plan. The average differences 
were relatively small (position on the ring: 10°, oblique 
angle: 8°, insertion depth: 4 mm). 
 
Conclusion: Individualized approach to cervical cancer 
patients with extensive parametrial involvement at the time 
of brachytherapy can contribute significantly to an improved 
dose coverage of the HR-CTV. An individualized 3D printed 
interstitial cap for the ring applicator with oblique needles is 
an efficient option for these patients. 
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Purpose or Objective: The aim is to report the results 
obtained in patients diagnosed of endometrial carcinoma 
stage IA-IIA treated with surgery followed by adyuvant 
brachytherapy at our institution. 
 
Material and Methods: From 2006 until 2013, 116 patients 
with endometrial carcinoma stage IA-IIA have been treated 
with surgery and exclusive vaginal brachytherapy. Median age 
of the series was 62 years. Total hysterectomy, double 
anexectomy, pelvic lymphadenectomy and peritoneal 
washing was made in 61,4 %. The majority of the 
pathologycal FIGO stages were IB (77,2 %). Exclusive 
brachytherapy was performed using vaginal cylinders with 3 
cm of diameter (50,9 %). The reference isodosis covering the 
proximal 3 cm of the vagina (96,4 %). The dose was specified 
at 5 mm distant from the surface of the cylinder. Dose 
schedule with high dose rate brachytherapy was 21 Gy in 3 
fractions. The median of dose equivalent received in the 
rectum was 31,8 Gy and in bladder 38 Gy. 
 
Results: At the moment of this analysis there are 4 relapses: 
2 of them live with disease, and 2 death for tumor; 110 cases 
live without disease (94,82 %), and 2 cases death for another 
cause. With median follow-up of 26 months, free disease 
survival was 90.2% and 2 years overall survival was 88.3%. No 
toxicity was reported in the 52,6%, and when it was present 
the most frequent was cystitis (12.3%).  
 
Conclusion: The exclusive vaginal brachytherapy is effective 
in ensuring vaginal control, with few toxic effects. So, this 
schedule should be an adyuvant treatment for these patients. 
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Purpose or Objective: The purpose of this study is to analyze 
the efficacy and complication rates of postoperative high 
dose rate (HDR) vaginal brachytherapy(VBT) to determine 
whether VBT with lower dose per fraction(3-4 Gy/fraction) is 
as effective as pelvic external beam radiotherapy (EBRT) for 
patients with stage 1 endometrial carcinoma 
 
Material and Methods: From March 2000 to April 2014, 43 
patients with FIGO stage I endometrial cancer underwent 
adjuvant radiotherapy following surgery. Twenty five 
patients received postoperative HDR VBT alone, while 18 
patients received postoperative EBRT to the whole pelvis. 
Among these patients, three patients were treated with EBRT 
plus VBT. The median treatment dose of EBRT was 50.0 Gy 
(45.0-50.4 Gy) and HDR VBT dose was five to six fractions of 3 
or 4 Gy to a total dose of 15-24 Gy. The tumor dose was 
prescribed at a depth of 5mm from the cylinder surface and 
delivered twice per week. 
 
Results: The median follow up period of all patients was 54.4 
(range 9-142) months. Five year disease free survivals (DFS) 
and overall survivals (OS) for all patients were 91.5% and 
91.2%, respectively. Five year DFS of EBRT and brachytherapy 
was 87.2% and 96.0%, respectively (p=0.46), and five year OS 
of EBRT and brachytherapy was 86.9% and 95.7%, respectively 
(p=0.43). There were no differences in 5 year DFS or OS 
according to radiation treatment group. There were no 
locoregional recurrences for all patients. Two patients who 
received EBRT and one patient who received brachytherapy 
alone developed distant metastatic disease. There were one 
patient who had grade 3 gastrointestinal complication and 
one patient who had pelvic bone insufficiency fracture. Two 
patients who had severe complication were treated with 
EBRT. 
 
Conclusion: HDR VBT with lower dose per fraction alone 
showed high DFS and OS with no severe adverse effect. HDR 
VBT with small fraction size may be adequate for early stage 
endometrial cancer following surgery. 
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Purpose or Objective: Controversies still exist in the method 
of treatment planning and applicator reconstruction in 
adaptive cervix brachytherapy. This study aims to compare 
any difference between MRI and CT applicator reconstruction 
and the treatment planning process at our institution. 
 
Material and Methods: Our analysis included 15 patients 
from our institution with stage IB2-IVA cervical cancers 
between January to October 2015, all patients treated with 
chemoradiation and brachytherapy. We followed the Vienna 
schedule for HDR brachytherapy at week 6 and 7, with 2 
weekly insertions with 2 consecutive fractions per week. MRI- 
and CT- based treatment planning and applicator 
reconstruction were done for every patient. Contours and 
dosimetry of tumor target (HRCTV D90) and organs at risk (D2cc 
bladder, rectum, sigmoid and small bowel) were compared. 
Applicator reconstruction techniques, possible challenges and 
errors between the 2 imaging modalities were analysed. 
 
Results: Both CT- and MR- based applicator reconstruction 
uncertainties were less than 1 mm for either tandem-and-
ovoids (T&O) or tandem-and-ring (T&R) applicators. 
Compared with T&O applicators, use of rigid T&R applicators 
gave more accurate applicator reconstruction. When an 
applicator library was used, the T&O reconstruction 
uncertainties always occurred in posterior-anterior direction 
while T&R reconstruction uncertainties were found when it 
rotated. Applicator holes for interstitial needles could 
provide additional markers to define correct applicator 
rotation on MRI. The D2cc rectum value was the most sensitive 
